Dixon-Douglas, Julia
Loi, Sherene http://orcid.org/0000-0001-6137-9171
Funding for this research was provided by:
University of Melbourne
Article History
Accepted: 19 March 2023
First Online: 24 May 2023
Compliance with Ethical Standards
:
: Sherene Loi receives research funding to her institution from Novartis, Bristol Meyers Squibb, Merck, Puma Biotechnology, Eli Lilly, Nektar Therapeutics Astra Zeneca, Roche-Genentech and Seattle Genetics. She has acted as consultant (not compensated) to Seattle Genetics, Novartis, Bristol Meyers Squibb, Merck, AstraZeneca and Roche-Genentech. She has acted as consultant (paid to her institution) to Aduro Biotech, Novartis, GlaxoSmithKline, Roche-Genentech, Astra Zeneca, Silverback Therapeutics, G1 Therapeutics, PUMA Biotechnologies, Pfizer, Gilead Therapeutics, Seattle Genetics and Bristol Meyers Squibb. Julia Dixon-Douglas reports no conflict of interest.
: This article does not contain any studies with human or animal subjects performed by any of the authors.